8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

July 6, 2005

MICRO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-06523	33-0569235
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2 Goodyear, Irvine, California 92618

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (949) 837-3700

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On July 6, 2005, Micro Therapeutics, Inc. issued a press release to report its net sales for the fiscal second quarter ended July 3, 2005. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(c)    Exhibits

Exhibit Number	Description
99.1	Press Release dated July 6, 2005.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MICRO THERAPEUTICS, INC.
July 7, 2005	/s/ Thomas Wilder
	Thomas C. Wilder, III, President and
	Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release dated July 6, 2005.

EX-99.1

EXHIBIT 99.1

Contacts:	Thomas C. Wilder
	Micro Therapeutics, Inc.
	949/837-3700
	Rob Whetstone/Robert Jaffe
	PondelWilkinson Inc.
	310/279-5963

Micro Therapeutics, Inc. Reports Sales Results for Second Quarter 2005

Net Sales Grow to $13.1 Million, a 44% Increase Compared

To Second Quarter 2004

Irvine, Calif. – July 7, 2005 – Micro Therapeutics, Inc. (MTI) (NASDAQ:MTIX), an endovascular medical device company focused on neurovascular disease and disorders, reported today net sales results for its fiscal second quarter ended July 3, 2005. Second quarter net sales results also were reported today by MTI’s majority shareholder, ev3 Inc. (NASDAQ: EVVV).

Net sales in the 2005 second quarter were $13.1 million, an increase of 44% versus net sales of $9.1 million in the second quarter of 2004, and an increase of 15% compared with net sales of $11.4 million in the preceding, first quarter of 2005. Compared with the year ago quarter, the primary contributors to the increase in MTI’s second quarter net sales were the company’s neuro embolic products, net sales of which increased by 30% to $4.2 million, and neuro access and delivery products, net sales of which increased by 60% to $8.1 million. Geographically, MTI’s second quarter net sales in the United States increased by 42% to $4.3 million, and second quarter international net sales increased by 45% to $8.8 million.

For the six months ended July 1, 2005, MTI’s net sales totaled $24.5 million, an increase of 47% compared to net sales during the first six months of 2004. Consistent with results for the second quarter, the primary contributors to the increase in MTI’s net sales growth for the first six months were the company’s neurovascular products.

About Micro Therapeutics, Inc.

Micro Therapeutics develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of vascular disease. The company is focused on catheter-based, or endovascular, technologies for the minimally invasive treatment of neurovascular disorders of the brain associated with stroke. MTI’s products include: the Tetris^® and NXT^® lines of embolic coils; the Onyx^® liquid embolic; and a range of access and delivery products that include micro delivery catheters, balloon catheters, and guidewires.

Micro Therapeutics, Inc.

2-2-2

Statements contained in this press release that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Such potential risks and uncertainties relate, but are not limited, to, in no particular order: product demand and market acceptance, the impact of competitive products and pricing, and success of clinical testing. More detailed information on these and additional factors which could affect Micro Therapeutics, Inc.’s operating and financial results are described in the company’s Forms 10-Q, 10-KSB, and other reports, filed or to be filed with the Securities and Exchange Commission. Micro Therapeutics, Inc. urges all interested parties to read these reports to gain a better understanding of the many business and other risks that the company faces. Additionally, Micro Therapeutics, Inc. undertakes no obligation to publicly release the results of any revisions to these forward-looking statements, which may be made to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.

# # #